Although we could not isolate the impact of anti-VEGF TKI in our cohort as all patients received systemic therapy, the similar prognosis of patients with and without tumour thrombus could be attributed to effective systemic therapy or because tumour thrombus is not prognostic for outcomes. The gene discussed is VEGFA; the disease is neoplasm.